Imugene Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
Leslie Chong
4.83yrs
Tenure
AU$1,153,580
Compensation
Ms. Leslie Chong serves as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21, 2016. Ms. Chon...
CEO Compensation Analysis
Date | Total Comp. | Salary | Company Earnings |
---|---|---|---|
Jun 30 2022 | AU$1m | AU$600k | -AU$38m |
Mar 31 2022 | n/a | n/a | -AU$33m |
Dec 31 2021 | n/a | n/a | -AU$27m |
Sep 30 2021 | n/a | n/a | -AU$23m |
Jun 30 2021 | AU$789k | AU$408k | -AU$18m |
Mar 31 2021 | n/a | n/a | -AU$15m |
Dec 31 2020 | n/a | n/a | -AU$12m |
Sep 30 2020 | n/a | n/a | -AU$11m |
Jun 30 2020 | AU$733k | AU$375k | -AU$11m |
Mar 31 2020 | n/a | n/a | -AU$10m |
Dec 31 2019 | n/a | n/a | -AU$9m |
Sep 30 2019 | n/a | n/a | -AU$8m |
Jun 30 2019 | AU$777k | AU$350k | -AU$8m |
Mar 31 2019 | n/a | n/a | -AU$7m |
Dec 31 2018 | n/a | n/a | -AU$6m |
Sep 30 2018 | n/a | n/a | -AU$5m |
Jun 30 2018 | AU$403k | AU$300k | -AU$4m |
Mar 31 2018 | n/a | n/a | -AU$3m |
Dec 31 2017 | n/a | n/a | -AU$3m |
Sep 30 2017 | n/a | n/a | -AU$3m |
Jun 30 2017 | AU$337k | AU$290k | -AU$3m |
Mar 31 2017 | n/a | n/a | -AU$3m |
Dec 31 2016 | n/a | n/a | -AU$3m |
Sep 30 2016 | n/a | n/a | -AU$3m |
Jun 30 2016 | AU$323k | AU$229k | -AU$3m |
Compensation vs Market: Leslie's total compensation ($USD819.94K) is about average for companies of similar size in the Australian market ($USD1.06M).
Compensation vs Earnings: Leslie's compensation has increased whilst the company is unprofitable.
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 10.25yrs | AU$350.00k | 4.94% A$ 46.0m | |
CEO, MD & Executive Director | 6.17yrs | AU$1.15m | 1.2% A$ 11.2m | |
Chief Technology Officer | no data | AU$490.82k | 0.29% A$ 2.7m | |
Chief Business Officer | 1.58yrs | AU$1.62m | no data | |
Chief Financial Officer | 0.33yr | no data | no data | |
Senior Vice President of Clinical Operations | 1yr | no data | no data | |
Chief Medical Officer | 0.25yr | no data | no data | |
Joint Company Secretary | 1.08yrs | no data | no data |
1.0yrs
Average Tenure
Experienced Management: IMU's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 10.25yrs | AU$350.00k | 4.94% A$ 46.0m | |
CEO, MD & Executive Director | 4.83yrs | AU$1.15m | 1.2% A$ 11.2m | |
Independent Non-Executive Director | 7.33yrs | AU$83.41k | 0.35% A$ 3.3m | |
Independent Non-Executive Director | 3.67yrs | AU$85.64k | 0.32% A$ 3.0m | |
Chair of Oncolytic Virotherapy Scientific Advisory Board | 3.17yrs | no data | 0% A$ 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | 8.75yrs | no data | no data | |
Member of Scientific Advisory Board | 4.25yrs | no data | no data | |
Scientific Advisory Board Member | 6.75yrs | no data | no data | |
Member of Scientific Advisory Board | 5.08yrs | no data | no data | |
Member of Scientific Advisory Board | 4.33yrs | no data | no data | |
Member of Scientific Advisory Board | 4.25yrs | no data | no data |
4.8yrs
Average Tenure
Experienced Board: IMU's board of directors are considered experienced (4.8 years average tenure).